Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Wojciech Jurczak(Jagiellonian University), Meng Ji(Masaryk University), Susan O’Brien(University of California, Irvine), Adam Idoine, Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Jennifer R. Brown(Dana-Farber Cancer Institute), Lugui Qiu(Chinese Academy of Medical Sciences & Peking Union Medical College), Tommi Salmi(Düsseldorf University Hospital), Andrzej Mital(Gdańsk Medical University), Habte Yimer(Texas Oncology), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Peter Ganly(European Bioinformatics Institute), Constantine S. Tam(The Alfred Hospital), Jessica L. Yecies, Anders Österborg(Karolinska University Hospital), Keshu Zhou(Zhengzhou University), Mazyar Shadman(University of Washington), Jiřı́ Mayer(Masaryk University), Amanda Gillespie-Twardy(Düsseldorf University Hospital), Sebastian Grosicki(Medical University of Silesia), Kenneth Wu(Düsseldorf University Hospital), Martin Šimkovič(Charles University), Tadeusz Robak(Medical University of Lodz), Barbara Eichhorst(University of Cologne), Jane Huang(University of Southern California), Maciej Kaźmierczak(Silesian University of Technology), Robert Weinkove(Malaghan Institute of Medical Research)
Cited by 93
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k